Benzinga
14 Aug 2026, 05:30 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Outlook Therapeutics announced the pricing of a $55.0 million public offering of common stock and warrants. — Equity offerings typically dilute existing shareholders, which is reflected in the immediate 19.2% price drop mentioned in the text.
-0.60Analysts expect the company to report a quarterly loss of 8 cents per share, an improvement over the 44 cents per share loss in the prior year. — A significant narrowing of losses suggests improving operational efficiency or lower expenses.
+0.30The consensus revenue estimate for the third quarter is $966.67 thousand, down from $1.5 million in the year-ago period. — Declining year-over-year revenue indicates a contraction in the company's top-line growth.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Recent analyst updates include a rating upgrade to 'Buy' from BTIG with a $4 price target and a price target increase to $1.6 from HC Wainwright. — Positive analyst sentiment and upward target revisions provide a bullish signal for long-term valuation.
+0.20Which stocks this story touches
The company's shares fell over 19% following the announcement of a $55 million public offering.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
